Wall Street Zen Upgrades Bausch + Lomb (NYSE:BLCO) to Strong-Buy

Bausch + Lomb (NYSE:BLCO) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday, Wall Street Zen reports.

BLCO has been the topic of several other research reports. Royal Bank Of Canada lifted their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company raised their price target on Bausch + Lomb from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Bausch + Lomb in a report on Friday, August 28th. UBS Group began coverage on shares of Bausch + Lomb in a research note on Thursday, July 30th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $20.00 target price on shares of Bausch + Lomb in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.75.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $19.99 on Friday. The stock has a market capitalization of $7.14 billion, a P/E ratio of -64.48, a PEG ratio of 0.53 and a beta of 0.52. The company has a 50 day moving average price of $17.35 and a 200 day moving average price of $16.69. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.04 and a current ratio of 1.56. Bausch + Lomb has a fifty-two week low of $14.44 and a fifty-two week high of $21.36.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS. Equities research analysts forecast that Bausch + Lomb will post 0.94 EPS for the current year.

Insider Activity at Bausch + Lomb

In related news, Director Eschenbach Andrew C. Von sold 6,059 shares of Bausch + Lomb stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $16.58, for a total transaction of $100,458.22. Following the completion of the sale, the director directly owned 63,733 shares of the company’s stock, valued at approximately $1,056,693.14. This trade represents a 8.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Frederick Munsch sold 52,900 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $769,044.18. The trade was a 53.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 71,459 shares of company stock worth $1,194,370 in the last 90 days. 1.45% of the stock is owned by company insiders.

Institutional Trading of Bausch + Lomb

Several hedge funds have recently modified their holdings of the company. Engineers Gate Manager LP purchased a new position in Bausch + Lomb during the 2nd quarter worth approximately $1,479,000. Beach Point Capital Management LP acquired a new stake in Bausch + Lomb during the third quarter valued at approximately $5,882,000. Whitebox Advisors LLC grew its position in Bausch + Lomb by 15.8% in the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after buying an additional 150,641 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after buying an additional 69,633 shares during the period. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of Bausch + Lomb during the third quarter worth $670,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Strong quarterly results: Bausch + Lomb reported adjusted earnings of $0.34 per share, well above the $0.21 consensus estimate, while revenue reached approximately $1.38 billion versus expectations of $1.37 billion. Revenue increased 7.3% year over year. Bausch + Lomb Q3 2026 Earnings
• Positive Sentiment: Higher 2026 guidance: Management raised its forecast to $5.450 billion-$5.550 billion in revenue and $1.090 billion-$1.140 billion in adjusted EBITDA, citing continued momentum from its Vision ’27 strategy. The improved outlook supports investor confidence in growth and profitability. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: Analysts raised targets: RBC lifted its price target from $21 to $23 and maintained an “outperform” rating. JPMorgan raised its target from $16 to $22, although it retained a “neutral” rating. The revisions indicate that analysts see improved earnings potential following the results. RBC Raises BLCO Price Target
• Neutral Sentiment: Deutsche Bank raised its target from $16 to $20 but kept a “hold” rating, while Wells Fargo increased its target from $18 to $19 and maintained an “equal weight” rating. These calls reflect more cautious views after the stock’s recent advance. Deutsche Bank Adjusts BLCO Price Target

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.